Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2016 - Global Markets Direct - Market Research

Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2016

Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2016 - Global Markets Direct - Market Research
Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2016
Published Jun 30, 2016
266 pages — Published Jun 30, 2016
Price US$ 1,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2016, provides an overview of the Takeda Pharmaceutical Company Limiteds pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Takeda Pharmaceutical Company Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Takeda Pharmaceutical Company Limited
- The report provides overview of Takeda Pharmaceutical Company Limited including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Takeda Pharmaceutical Company Limiteds pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Takeda Pharmaceutical Company Limiteds out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Takeda Pharmaceutical Company Limiteds strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Takeda Pharmaceutical Company Limited
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Takeda Pharmaceutical Company Limiteds pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective p

  
Source:
Document ID
GMDHC08080CDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents213
  List of Tables141
  List of Figures141
Takeda Pharmaceutical Company Limited Snapshot151
  Takeda Pharmaceutical Company Limited Overview151
  Key Information151
  Key Facts151
Takeda Pharmaceutical Company Limited Research and Development Overview167
  Key Therapeutic Areas167
Takeda Pharmaceutical Company Limited Pipeline Review237
  Pipeline Products by Stage of Development231
  Pipeline Products Monotherapy241
  Pipeline Products Combination Treatment Modalities251
  Pipeline Products Partnered Products261
    Partnered Products/Combination Treatment Modalities271
  Pipeline Products Out-Licensed Products281
    Out-Licensed Products/Combination Treatment Modalities291
Takeda Pharmaceutical Company Limited Pipeline Products Glance3011
  Takeda Pharmaceutical Company Limited Late Stage Pipeline Products301
    Pre-Registration Products/Combination Treatment Modalities301
    Filing rejected/Withdrawn Products/Combination Treatment Modalities311
    Phase III Products/Combination Treatment Modalities321
  Takeda Pharmaceutical Company Limited Clinical Stage Pipeline Products331
    Phase II Products/Combination Treatment Modalities331
    Phase I Products/Combination Treatment Modalities341
    Phase 0 Products/Combination Treatment Modalities351
  Takeda Pharmaceutical Company Limited Early Stage Pipeline Products361
    IND/CTA Filed Products/Combination Treatment Modalities361
    Preclinical Products/Combination Treatment Modalities373
    Discovery Products/Combination Treatment Modalities401
Takeda Pharmaceutical Company Limited Drug Profiles41133
  (alogliptin benzoate + metformin hydrochloride)411
    Product Description411
    Mechanism of Action411
    R&D Progress412
  (alogliptin benzoate + pioglitazone hydrochloride)431
    Product Description431
    Mechanism of Action431
    R&D Progress433
  brentuximab vedotin461
    Product Description461
    Mechanism of Action461
    R&D Progress467
  ceftaroline fosamil531
    Product Description531
    Mechanism of Action531
    R&D Progress533
  ixazomib citrate561
    Product Description561
    Mechanism of Action561
    R&D Progress565
  ramelteon611
    Product Description611
    Mechanism of Action611
    R&D Progress612
  vedolizumab631
    Product Description631
    Mechanism of Action631
    R&D Progress632
  roflumilast651
    Product Description651
    Mechanism of Action651
    R&D Progress655
  (amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide)701
    Product Description701
    Mechanism of Action701
    R&D Progress701
  azilsartan medoxomil711
    Product Description711
    Mechanism of Action711
    R&D Progress712
  febuxostat XR731
    Product Description731
    Mechanism of Action731
    R&D Progress731
  immune globulin (human)741
    Product Description741
    Mechanism of Action741
    R&D Progress742
  pioglitazone hydrochloride761
    Product Description761
    Mechanism of Action761
    R&D Progress762
  rasagiline mesylate781
    Product Description781
    Mechanism of Action781
    R&D Progress781
  relugolix791
    Product Description791
    Mechanism of Action791
    R&D Progress791
  TAK-003801
    Product Description801
    Mechanism of Action801
    R&D Progress803
  vortioxetine hydrobromide831
    Product Description831
    Mechanism of Action831
    R&D Progress833
  AM-4861
    Product Description861
    Mechanism of Action861
    R&D Progress861
  DSM-265871
    Product Description871
    Mechanism of Action871
    R&D Progress872
  namilumab891
    Product Description891
    Mechanism of Action891
    R&D Progress892
  TAK-063911
    Product Description911
    Mechanism of Action911
    R&D Progress912
  TAK-214931
    Product Description931
    Mechanism of Action931
    R&D Progress932
  TAK-272951
    Product Description951
    Mechanism of Action951
    R&D Progress951
  TAK-850961
    Product Description961
    Mechanism of Action961
    R&D Progress962
  J-591981
    Product Description981
    Mechanism of Action981
    R&D Progress981
  TAK-020991
    Product Description991
    Mechanism of Action991
    R&D Progress991
  TAK-0211001
    Product Description1001
    Mechanism of Action1001
    R&D Progress1001
  TAK-0581011
    Product Description1011
    Mechanism of Action1011
    R&D Progress1011
  TAK-0711021
    Product Description1021
    Mechanism of Action1021
    R&D Progress1021
  TAK-0791031
    Product Description1031
    Mechanism of Action1031
    R&D Progress1031
  TAK-6531041
    Product Description1041
    Mechanism of Action1041
    R&D Progress1041
  TAK-7921051
    Product Description1051
    Mechanism of Action1051
    R&D Progress1051
  TAK-8281061
    Product Description1061
    Mechanism of Action1061
    R&D Progress1061
  TAK-8311071
    Product Description1071
    Mechanism of Action1071
    R&D Progress1071
  TAK-9151081
    Product Description1081
    Mechanism of Action1081
    R&D Progress1081
  TAK-9351091
    Product Description1091
    Mechanism of Action1091
    R&D Progress1091
  trelagliptin succinate1101
    Product Description1101
    Mechanism of Action1101
    R&D Progress1102
  (plague + small pox) vaccine1121
    Product Description1121
    Mechanism of Action1121
    R&D Progress1121
  BTZO-21131
    Product Description1131
    Mechanism of Action1131
    R&D Progress1131
  chikungunya vaccine1141
    Product Description1141
    Mechanism of Action1141
    R&D Progress1141
  ELQ-3001151
    Product Description1151
    Mechanism of Action1151
    R&D Progress1151
  influenza [strain A/H5N1] vaccine1161
    Product Description1161
    Mechanism of Action1161
    R&D Progress1161
  influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine1171
    Product Description1171
    Mechanism of Action1171
    R&D Progress1171
  mapatumumab1181
    Product Description1181
    Mechanism of Action1181
    R&D Progress1182
  Monoclonal Antibody Conjugate to Target c-Ret for Breast Cancer1201
    Product Description1201
    Mechanism of Action1201
    R&D Progress1201
  Monoclonal Antibody Conjugate to Target Guanylyl Cyclase C for Oncology1211
    Product Description1211
    Mechanism of Action1211
    R&D Progress1211
  Monoclonal Antibody Conjugates for Oncology1221
    Product Description1221
    Mechanism of Action1221
    R&D Progress1221
  respiratory syncytial virus (virus like particle) vaccine1231
    Product Description1231
    Mechanism of Action1231
    R&D Progress1231
  Rotavirus (virus like particle) vaccine1241
    Product Description1241
    Mechanism of Action1241
    R&D Progress1241
  Small Molecule 1 to Inhibit Dopamine Transporter, Noradrenaline Transporter and Serotonin Transporter for Depression1251
    Product Description1251
    Mechanism of Action1251
    R&D Progress1251
  Small Molecule 2 to Inhibit Gamma Secretase for Alzheimer's Disease1261
    Product Description1261
    Mechanism of Action1261
    R&D Progress1261
  Small Molecule to Activate Glucokinase for Type 2 Diabetes1271
    Product Description1271
    Mechanism of Action1271
    R&D Progress1271
  Small Molecule to Agonize Cannabinoid Receptor for Inflammatory Pain1281
    Product Description1281
    Mechanism of Action1281
    R&D Progress1281
  Small Molecule to Agonize GPR52 for Psychiatry Disorders1291
    Product Description1291
    Mechanism of Action1291
    R&D Progress1291
  Small Molecule to Antagonize Androgen Receptor for Prostate Cancer1301
    Product Description1301
    Mechanism of Action1301

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Takeda-Pharmaceutical-Company-Limited-Product-Pipeline-Review-2016-2088-16071>
  
APA:
Global Markets Direct - Market Research. (2016). Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Takeda-Pharmaceutical-Company-Limited-Product-Pipeline-Review-2016-2088-16071>
  
US$ 1,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.